Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China

被引:7
|
作者
Li, Heng
Xiong, Wenjie
Liu, Huimin
Yi, Shuhua
Yu, Zhen
Liu, Wei
Lyu, Rui
Wang, Tingyu
Zou, Dehui
Li, Zengjun
Qiu, Lugui
机构
[1] Chinese Acad Med Sci, State Key Lab Expt Hematol, Inst Hematol, Tianjin 300020, Peoples R China
[2] Chinese Acad Med Sci, Blood Dis Hosp, Tianjin 300020, Peoples R China
[3] Peking Union Med Coll, Tianjin 300020, Peoples R China
[4] Chinese Acad Med Sci, Dept Lymphoma & Myeloma, Inst Hematol, Tianjin 300020, Peoples R China
关键词
17p deletion; chronic lymphocytic leukemia (CLL); fluorescent in situ hybridization (FISH); del17p in CLL; HIGH-DOSE METHYLPREDNISOLONE; LRF CLL4 TRIAL; RITUXIMAB; THERAPY; CYCLOPHOSPHAMIDE; FLUDARABINE; SURVIVAL; ABNORMALITIES; ALEMTUZUMAB; ABERRATIONS;
D O I
10.21147/j.issn.1000-9604.2017.02.09
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective: This study aims to evaluate the natural history of patients with chronic lymphocytic leukemia (CLL) and a 17p deletion (17p-) and identify the predictive factors within this subgroup. Methods: The sample of patients with CLL were analyzed by fluorescence in situ hybridization for deletions in chromosome bands 11q22, 13q14 and 17p13; trisomy of bands 12q13; and translocation involving band 14q32. The data from 456 patients with or without a 17p-were retrospectively collected and analyzed. Results: The overall response rate (ORR) in patients with a 17p- was 56.9%, and patients with a high percentage of 17p-(defined as more than 25% of cells harbouring a 17p-) had a lower ORR. The median overall survival (OS) in patients with a 17p-was 78.0 months, which was significantly shorter than the OS in patients without this genetic abnormality (median 162.0 months, P<0.001). Within the subgroup with a 17p-, the progression-free survival was significantly shorter in patients at Binet stage B-C and patients with elevated lactate dehydrogenase (LDH), B symptoms, unmutated IGHV and a high percentage of 17p-. Conclusions: These results indicated that patients with a 17p- CLL have a variable prognosis that might be predicted using simple clinical and laboratory characteristics.
引用
收藏
页码:156 / 165
页数:10
相关论文
共 50 条
  • [1] Serum LDH level may predict outcome of chronic lymphocytic leukemia patients with a 17p deletion: a retrospective analysis of prognostic factors in China
    Heng Li
    Wenjie Xiong
    Huimin Liu
    Shuhua Yi
    Zhen Yu
    Wei Liu
    Rui Lyu
    Tingyu Wang
    Dehui Zou
    Zengjun Li
    Lugui Qiu
    ChineseJournalofCancerResearch, 2017, 29 (02) : 156 - 165
  • [2] Chronic lymphocytic leukaemia with 17p deletion: a retrospective analysis of prognostic factors and therapy results
    Delgado, Julio
    Espinet, Blanca
    Oliveira, Ana C.
    Abrisqueta, Pau
    de la Serna, Javier
    Collado, Rosa
    Loscertales, Javier
    Lopez, Montserrat
    Hernandez-Rivas, Jose A.
    Ferra, Christelle
    Ramirez, Angel
    Roncero, Josep M.
    Lopez, Cristina
    Aventin, Anna
    Puiggros, Anna
    Abella, Eugenia
    Carbonell, Felix
    Costa, Dolors
    Carrio, Anna
    Gonzalez, Marcos
    BRITISH JOURNAL OF HAEMATOLOGY, 2012, 157 (01) : 67 - 74
  • [3] Pharmacokinetics of venetoclax in patients with 17p deletion chronic lymphocytic leukemia
    Salem, Ahmed Hamed
    Dunbar, Martin
    Agarwal, Suresh K.
    ANTI-CANCER DRUGS, 2017, 28 (08) : 911 - 914
  • [4] The percentage of cells with 17p deletion and the size of 17p deletion subclones show prognostic significance in chronic lymphocytic leukemia
    Yuan, Ying-Ying
    Zhu, Hua-Yuan
    Wu, Jia-Zhu
    Xia, Yi
    Liang, Jin-Hua
    Wu, Wei
    Cao, Lei
    Wang, Li
    Fan, Lei
    Li, Jian-Yong
    Xu, Wei
    GENES CHROMOSOMES & CANCER, 2019, 58 (01): : 43 - 51
  • [5] Chronic lymphocytic leukemia with deletion 17p: An Indian scenario
    Gogia, Ajay
    Gupta, Ritu
    Kumar, Lalit
    Sharma, Atul
    Soni, Lata
    SOUTH ASIAN JOURNAL OF CANCER, 2019, 8 (01) : 40 - +
  • [6] FRONTLINE TREATMENT OF CHRONIC LYMPHOCYTIC LEUKEMIA WITH DELETION 17P
    Strati, P.
    Keating, M.
    O'Brien, S.
    Ferrajoli, A.
    Burger, J.
    Faderl, S.
    Jain, N.
    Wierda, W.
    HAEMATOLOGICA, 2013, 98 : 45 - 45
  • [7] Treatment of patients with chronic lymphocytic leukemia with 17p deletion: the saga continues
    Castro, Januario E.
    LEUKEMIA & LYMPHOMA, 2012, 53 (02) : 179 - 180
  • [8] TRANSLOCATION IS A FREQUENT MECHANISM FOR 17P DELETION IN PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA
    Sobotka, J.
    Breicha, M.
    Brychtova, Y.
    Doubek, M.
    Holubova, V.
    Tovarysova, A.
    Stoklasova, M.
    Czekajova, A.
    Sablaturova, T.
    Wrobel, M.
    Klodova, D.
    Bogoczova, E.
    Adamova, D.
    Heinzova, V.
    Zivna, J.
    Plevova, K.
    Pospisilova, S.
    Mayer, J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 40 - 40
  • [9] Incidence and outcome of chronic lymphocytic leukemia with deletion 17p: An Indian experience; challenges and opportunities
    Gogia, A.
    Kumar, L.
    Sharma, A.
    Gupta, R.
    Rani, L.
    ANNALS OF ONCOLOGY, 2019, 30
  • [10] Allogeneic hematopoietic cell transplantation for chronic lymphocytic leukemia (CLL) with 17p deletion: A retrospective EBMT analysis
    Schetelig, Johannes
    van Biezen, Anja
    Caballero, Dolores
    Rodrigo, Martino
    Remes, Kari
    Garcia-Marco, Jose A.
    Volin, Liisa
    Perez-Simon, Jose A.
    Schmitz, Norbert
    Schwerdtfeger, Rainer
    Ganser, Arnold
    Soligo, Davide
    Mohr, Brigitte
    Stilgenbauer, Stephan
    Brand, Ronald
    Ehninger, Gerhard
    de Witte, Theo
    Dreger, Peter
    BLOOD, 2007, 110 (11) : 22A - 23A